(SeaPRwire) –   By: Oliver Hawthorne

The biotech industry faces a quiet crisis. Ninety percent of oncology drugs fail in clinical trials. The root? We’ve been chasing data volume instead of diversity.

Phinomics, a biotech group, is joining “All Access hosted by Andy Garcia” to change that. For decades, researchers knew about circular DNA—tiny, fragile genetic circles in cells—but couldn’t isolate them without breaking them. These circles hold clues to how cells adapt and resist treatments. Phinomics uses modern computational tools to extract them intact. Their co-founder, Massa Shoura, says biology needs explainable AI trained on diverse, matched data (not just trillions of identical measurements). This multi-layered approach (combining RNA, proteins, circular DNA) gives a truer picture of cellular behavior.

Here’s the commercial end-game: Biotechs that shift to multi-modal data and explainable AI will cut trial failures. Phinomics’ platform isn’t just a research tool—it’s a blueprint for the next wave of therapies. The industry will no longer waste resources on volume; it will prioritize the right data to unlock real breakthroughs.

Author bio: Oliver Hawthorne, Principal Correspondent at an international tech review, covers biotech and AI intersections.